RAPT Therapeutics, Inc. (RAPT)

Market Cap	281.86M
Revenue (ttm)	n/a
Net Income (ttm)	-116.80M
Shares Out	34.80M
EPS (ttm)	-3.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	294,633
Open	7.87
Previous Close	7.80
Day's Range	7.67 - 8.31
52-Week Range	6.86 - 27.35
Beta	0.47
Analysts	Buy
Price Target	22.29 (+175.19%)
Earnings Date	May 9, 2024

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 31, 2019
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPT

Analyst Forecast

According to 10 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is $22.29, which is an increase of 175.19% from the latest price.

Price Target

$22.29

(175.19% upside)

Analyst Consensus: Buy